Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/978-1-4899-2064-5_5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Venetoclax plus azacitidine represents a key advance for older, unfit patients with acute myeloid leukemia (AML). The chemotherapy and venetoclax in elderly AML trial (CAVEAT) was first to combine venetoclax with intensive chemotherapy in newly diagnosed patients ≥65 years. In this final analysis, 85 patients (median age 71 years) were followed for a median of 41.
View Article and Find Full Text PDFOxytocin levels in response to CRH administration in hypopituitarism and hypothalamic damage: a randomized, crossover, placebo-controlled trial.
Sci Rep
January 2025
Department of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau, IR-SANT PAU, CIBERER-U747 ISCIII, ENDO-ERN, Barcelona, Spain.
Increasing evidence supports the presence of oxytocin deficiency (OXT-D) in patients with hypopituitarism and hypothalamic damage (HHD), that might be associated with neuropsychological deficits and sexual dysfunction, leading to worse quality of life (QoL). Therefore, identifying a provocative test to diagnose an OXT-D will be important. Corticotropin-releasing hormone (CRH) is a candidate for such a test as it increases oxytocin secretion in animal models.
View Article and Find Full Text PDFOlutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial.
J Hematol Oncol
January 2025
Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Background: Olutasidenib is a potent, selective, oral, small molecule inhibitor of mutant IDH1 (mIDH1) which induced durable remissions in high-risk, relapsed/refractory (R/R) mIDH1 AML patients in a phase 1/2 trial. We present a pooled analysis from multiple cohorts of the phase 1/2 trial of patients with R/R AML who received combination olutasidenib and azacitidine therapy.
Methods: Adult patients with mIDH1 AML received 150 mg olutasidenib twice daily plus standard-of-care azacitidine (OLU + AZA) and were evaluated for response and safety.
Combination ATR-FTIR with Multiple Classification Algorithms for Authentication of the Four Medicinal Plants from L. in Rhizomes and Tuberous Roots.
Sensors (Basel)
December 2024
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Curcumae Longae Rhizoma (CLRh), Curcumae Radix (CRa), and Curcumae Rhizoma (CRh), derived from the different medicinal parts of the species, are blood-activating analgesics commonly used for promoting blood circulation and relieving pain. Due to their certain similarities in chemical composition and pharmacological effects, these three herbs exhibit a high risk associated with mixing and indiscriminate use. The diverse methods used for distinguishing the medicinal origins are complex, time-consuming, and limited to intraspecific differentiation, which are not suitable for rapid and systematic identification.
View Article and Find Full Text PDFEvaluation of the Anxiolytic and Antidepressant Effects of Standardized Ashwagandha () Root Extract in Wistar Rats.
Prev Nutr Food Sci
December 2024
Food Science R&D Center, Kolmar BNH, Seoul 06800, Korea.
Ashwagandha () is a popular herb in Ayurveda, the traditional medicine system in India. It is known to exert stress-mitigating properties and has been extensively studied for its safety and efficacy in various disorders. This study assessed the effects of Ashwagandha root extract (ARE) on stress in rats.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!